Review

anti 146 jag1 antibody (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc anti 146 jag1 antibody
Anti 146 Jag1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jag1+antibody/pm40912393-98-7-10
Average 86 stars, based on 1 article reviews

anti 146 jag1 antibody - by Bioz Stars, 2026-09

86/100 stars

Images

Western Blot:

Article Title: Long non-coding RNA Malat1 fine-tunes bone homeostasis and repair by orchestrating cellular crosstalk and β-catenin-OPG/Jagged1 pathway
Article Snippet: Cell lysates were fractionated on 7.5% SDS-PAGE, transferred to Immobilon-P membranes (0.45 μm, Millipore), and incubated with specific antibodies. .. Western Lightning Plus-ECL (PerkinElmer) was used for detection. β-catenin antibody (9562, 1:1000) and Jag1 antibody (70109, 1:1000) were obtained from Cell Signaling Technology. .. Nfatc1 antibody (556602, 1:1000) was obtained from BD Biosciences; Blimp1 (sc-47732, 1:1000), c-Fos (sc-52, 1:1000), OPG/Osteoprotegerin (sc-390518, 1:1000) and p38α (sc-535, 1:3000) antibodies were purchased from Santa Cruz Biotechnology.

Article Title: Malatl fine-tunes bone homeostasis by orchestrating cellular crosstalk and the β-catenin-OPG/Jagged1 pathway
Article Snippet: Cell lysates were fractionated on 7.5% SDS- PAGE, transferred to Immobilon- P membranes (0.45 μm, Millipore), and incubated with specific antibodies. .. Western Lightning Plus- ECL (PerkinElmer) was used for detection. β-catenin antibody (9562, 1:1000) and Jag1 antibody (70109, 1:1000) were obtained from Cell Signaling Technology. .. Nfatc1 antibody (556602, 1:1000) was obtained from BD Biosciences; Blimp1 (sc- 47732, 1:1000), c- Fos (sc- 52, 1:1000), OPG/Osteoprotegerin (sc- 390518, 1:1000) and p38α (sc- 535, 1:3000) antibodies were purchased from Santa Cruz Biotechnology.

Article Title: Long non-coding RNA Malat1 is essential for fine-tuning bone homeostasis through orchestrating cellular crosstalk and the β-catenin-OPG/Jagged1 pathway
Article Snippet: Cell lysates were fractionated on 7.5% SDS-PAGE, transferred to Immobilon-P membranes (0.45 μm, Millipore), and incubated with specific antibodies. .. Western Lightning Plus-ECL (PerkinElmer) was used for detection. β-catenin antibody (9562, 1:1000) and Jag1 antibody (70109, 1:1000) were obtained from Cell Signaling Technology. .. Nfatc1 antibody (556602, 1:1000) was obtained from BD Biosciences; Blimp1 (sc- 14 47732, 1:1000), c-Fos (sc-52, 1:1000), OPG/Osteoprotegerin (sc-390518, 1:1000) and p38α (sc-535, 1:3000) antibodies were purchased from Santa Cruz Biotechnology.

other:

Article Title: The Notch1 intracellular domain orchestrates mechanotransduction of fluid shear stress
Article Snippet: Antibodies against Notch1 V1754 (V1744 in mice, D3B8, 1:500 WB), Notch1 ICD (D1E11, 1:200 IF, 1:1000 WB), GAPDH (14C10, 1:5000 WB), Dll4 (D7N3H, 1:1000 WB), Jag1 (D4Y1R, 1:1000 WB), GFP (D5.1, 1:5000 WB), Annexin A2 (D11G2, 1:1000 WB, 1:200 IF), Presenilin-1 (E3L9X, 1:1000 WB), and Flotillin-2 (C42A3, 1:1000 WB) were from Cell Signaling Technologies.

Article Title: miR-34a-5p modulation of polycystic ovary syndrome via targeting the NOTCH signaling pathway.
Article Snippet: The subsequent principal antibodies were utilised in the analyses: JAG1 (CST, USA), NICD (CST, USA), Notch (ZEN-BIOSCIENCE, China), Bcl-2 (Elabscience, China), Bax (Elabscience, China), caspase-3 (Elabscience, China), caspase-9 (Elabscience, China), Hes1 (ZEN-BIOSCIENCE, China), and Hey1 (Affinity, China).

Article Title: A Wnt10a-Notch signaling axis controls Hertwig’s epithelial root sheath cell behaviors during root furcation patterning
Article Snippet: Following antigen retrieval (ZSGB-BIO, Beijing, China), sections were blocked for 1 h at room temperature in blocking solution (ZSGB-BIO), and incubated with primary antibodies against E-Cadherin (1:100; ab76319, Abcam, Cambridge, UK), Acetyl-α-Tubulin (1:100; Cell Signaling Technology (CST), Danvers, USA), Cyclin D1 (1:100; CST), Notch2 (1:50; CST), or Jag1 (1:50; CST), overnight at 4 °C.

Staining:

Article Title: Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion
Article Snippet: .. The samples were stained with JAG1 antibody (1:200, Cat. #70109; Cell Signaling Technology) overnight at 4 °C, washed three times for 5 min each in ice-cold PBS, and incubated with Alexa 488 conjugated secondary antibody (1:400, Cat. #A32731, and #A28175; Invitrogen) or Alexa 594 conjugated secondary antibody (1:400, Cat. #A11012 and #11032; Invitrogen) at 25 °C for 2 h. After staining with DAPI (1:1,000, Cat. #D9542; Sigma-Aldrich) for 5 min, slides were mounted in mounting solution (Cat. #P36930; Invitrogen) and stored at 4 °C in the dark. .. Fluorescence was detected using a confocal laser-scanning microscope (LSM800; Carl Zeiss).

Article Title: Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion.
Article Snippet: .. The samples were stained with JAG1 antibody (1:200, Cat. #70109; Cell Signaling Technology) overnight at 4 °C, washed three times for 5 min each in ice-cold PBS, and incubated with Alexa 488 conjugated secondary antibody (1:400, Cat. #A32731, and #A28175; Invitrogen) or Alexa 594 conjugated secondary antibody (1:400, Cat. #A11012 and #11032; Invitrogen) at 25 °C for 2 h. After staining with DAPI (1:1,000, Cat. #D9542; Sigma-Aldrich) for 5 min, slides were mounted in mounting solution (Cat. #P36930; Invitrogen) and stored at 4 °C in the dark. .. Fluorescence was detected using a confocal laser-scanning microscope (LSM800; Carl Zeiss).

Incubation:

Image Search Results

Stepwise differentiation of iPSCs into SGN-enriched organoids and early phenotypic differences in TMPRSS3-deficient clones (A) Schematic overview of the stepwise differentiation protocol. Human iPSCs were expanded in E8 medium, transferred to serum-free (SF) medium, and subsequently directed toward the otic lineage using DFNB medium under feeder-free conditions. (B) Phase-contrast images showing morphological changes during differentiation: adherent iPSC colonies (iPSCs), early aggregates (day 6 and day 9), spherical organoids (day 15), and progressively larger structures (day 25, day 45, and day 70). (C–N) Pluripotency validation of K2/8 WT (C–H) and K2/8 C4 KO (I–N) iPSCs. Nuclear markers NANOG (C, I), OCT4 (D, J), SOX2 (E, K) and surface markers SSEA4 (F, L), TRA-1-60 (G, M), TRA-1-81 (H, N) confirm robust pluripotency of all lines. (O–V) Early otic differentiation at days 3, 6, 9, and 11 in K2/8 WT (O, Q, S, U) and K2/8 C4 KO (P, R, T, V) organoids. (O, P) Day 3: K2/8 WT organoids show diffuse EYA1, ECAD + epithelial boundaries, and DLX5 + cells, whereas K2/8 C4 organoids display perinuclear EYA1, larger ECAD + cells, and no DLX5. (Q, R) Day 6: K2/8 WT retains strong nuclear SOX2 and ECAD; K2/8 C4 shows loss of SOX2 + progenitors and collapsed ECAD expression. (S, T) Day 9: K2/8 WT exhibits nuclear PAX8 + progenitors within organized ECAD + epithelium; K2/8 C4 shows condensed ECAD and reduced PAX8.U, V) Day 11: K2/8 WT expresses not PAX8 and JAG1; K2/8 C4 shows early JAG1 and absent PAX8 expression. Representative images were obtained from n ≥ 3 organoids per time point from four independent differentiation experiments. Scale bars, 20 μm (B: iPSCs, d6, d9, C-N, O′-V′), 100 μm (B: d15, d25, O-V), and 500 μm (B: d45, d70). Nuclei were counterstained with DAPI (blue). See also .

Journal: iScience

Article Title: Otic organoids: A model to study spiral ganglion neuron characteristics in Tmprss3-deficiency

doi: 10.1016/j.isci.2025.114355

Figure Lengend Snippet: Stepwise differentiation of iPSCs into SGN-enriched organoids and early phenotypic differences in TMPRSS3-deficient clones (A) Schematic overview of the stepwise differentiation protocol. Human iPSCs were expanded in E8 medium, transferred to serum-free (SF) medium, and subsequently directed toward the otic lineage using DFNB medium under feeder-free conditions. (B) Phase-contrast images showing morphological changes during differentiation: adherent iPSC colonies (iPSCs), early aggregates (day 6 and day 9), spherical organoids (day 15), and progressively larger structures (day 25, day 45, and day 70). (C–N) Pluripotency validation of K2/8 WT (C–H) and K2/8 C4 KO (I–N) iPSCs. Nuclear markers NANOG (C, I), OCT4 (D, J), SOX2 (E, K) and surface markers SSEA4 (F, L), TRA-1-60 (G, M), TRA-1-81 (H, N) confirm robust pluripotency of all lines. (O–V) Early otic differentiation at days 3, 6, 9, and 11 in K2/8 WT (O, Q, S, U) and K2/8 C4 KO (P, R, T, V) organoids. (O, P) Day 3: K2/8 WT organoids show diffuse EYA1, ECAD + epithelial boundaries, and DLX5 + cells, whereas K2/8 C4 organoids display perinuclear EYA1, larger ECAD + cells, and no DLX5. (Q, R) Day 6: K2/8 WT retains strong nuclear SOX2 and ECAD; K2/8 C4 shows loss of SOX2 + progenitors and collapsed ECAD expression. (S, T) Day 9: K2/8 WT exhibits nuclear PAX8 + progenitors within organized ECAD + epithelium; K2/8 C4 shows condensed ECAD and reduced PAX8.U, V) Day 11: K2/8 WT expresses not PAX8 and JAG1; K2/8 C4 shows early JAG1 and absent PAX8 expression. Representative images were obtained from n ≥ 3 organoids per time point from four independent differentiation experiments. Scale bars, 20 μm (B: iPSCs, d6, d9, C-N, O′-V′), 100 μm (B: d15, d25, O-V), and 500 μm (B: d45, d70). Nuclei were counterstained with DAPI (blue). See also .

Article Snippet: JAG1 , Santa Cruz , Sc-390177.

Techniques: Clone Assay, Biomarker Discovery, Expressing

Otic patterning and neuronal differentiation in WT and TMPRSS3-deficient organoids (A) Day 16 K2/8 WT organoid showing compartmentalization into ECAD + otocyst-like epithelium (red) and JAG1 + protruding domain (green). Schematic illustration (center) indicates spatial organization. (B, D) Day 25 K2/8 WT organoids expressing PAX8 and JAG1, together with SOX2 + progenitors and POU4F1 + neuronal precursors. (C, E) Day 25 K2/8 C4 KO organoids also expressed PAX8 and JAG1, but lacked SOX2 and POU4F1, indicating absence of progenitors and early neuronal specification. (F, G) Day 45 WT organoids display MAP2 + neurites co-expressing PRH (F) or POU4F1 (G). PRH is typically associated with type II SGNs, while POU4F1 marks type I SGNs, indicating the emergence of both major SGN subtypes at this stage. (H, H′) Day 70 WT organoids showing TMPRSS3 expression (red) co-localizing with PRH (green) in neuronal cell bodies. Higher magnification (H′) highlights TMPRSS3 + /PRH + neurons. Representative images were obtained from n ≥ 3 organoids per time point from four independent differentiation experiments. Scale bars, 100 μm (A–H) and 10 μm (H′). Nuclei were counterstained with DAPI (blue). See also .

Journal: iScience

Article Title: Otic organoids: A model to study spiral ganglion neuron characteristics in Tmprss3-deficiency

doi: 10.1016/j.isci.2025.114355

Figure Lengend Snippet: Otic patterning and neuronal differentiation in WT and TMPRSS3-deficient organoids (A) Day 16 K2/8 WT organoid showing compartmentalization into ECAD + otocyst-like epithelium (red) and JAG1 + protruding domain (green). Schematic illustration (center) indicates spatial organization. (B, D) Day 25 K2/8 WT organoids expressing PAX8 and JAG1, together with SOX2 + progenitors and POU4F1 + neuronal precursors. (C, E) Day 25 K2/8 C4 KO organoids also expressed PAX8 and JAG1, but lacked SOX2 and POU4F1, indicating absence of progenitors and early neuronal specification. (F, G) Day 45 WT organoids display MAP2 + neurites co-expressing PRH (F) or POU4F1 (G). PRH is typically associated with type II SGNs, while POU4F1 marks type I SGNs, indicating the emergence of both major SGN subtypes at this stage. (H, H′) Day 70 WT organoids showing TMPRSS3 expression (red) co-localizing with PRH (green) in neuronal cell bodies. Higher magnification (H′) highlights TMPRSS3 + /PRH + neurons. Representative images were obtained from n ≥ 3 organoids per time point from four independent differentiation experiments. Scale bars, 100 μm (A–H) and 10 μm (H′). Nuclei were counterstained with DAPI (blue). See also .

Article Snippet: JAG1 , Santa Cruz , Sc-390177.

Techniques: Expressing

a UMAP of single-cell RNA-sequencing from day 10 (pre-treatment), day 12 control, and day 12 PI3K inhibitor (LY294002)-treated kidney organoid nephrons. Cells are colored by sample with marker gene annotations. b Heatmap of Z-scores for hierarchically clustered differentially expressed genes across samples. Representative genes are listed, with a Z-score legend. c Feature plots of genes enriched in each sample group from the differentially expressed gene list. d Feature plots of selected genes for each group based on sample characteristics. For c , d human nephron single-cell detection (Supplementary Fig. ) is shown on the left, organoid plot on the right. e UMAP of single-cell RNA-sequencing from day 12 control and day 12 LY294002-treated kidney organoid nephrons. Cells match a but exclude day 10 sample. Cells are colored by sample with marker gene annotations. f Heatmap of log 2 fold change (log 2 FC) for differentially expressed genes, calculated as the ratio of LY294002-treated to control aggregate expression. Representative genes are listed with a log 2 FC legend. g Feature plots of genes enriched in each sample from the differentially expressed gene list. Human nephron single-cell (Supplementary Fig. ) detection is on the left, organoid plot on the right. h Split violin plots of genes from the differentially expressed gene list. Top two rows show genes enriched in day 12 control cells; bottom two rows show genes enriched in day 12 LY294002-treated cells. Plot colors match sample colors from ( e ). i Gene ontology terms for the top 50 differentially expressed genes per sample. Top graph: day 12 control nephron cells; bottom graph: LY294002-treated nephron cells. j–l Whole-mount immunofluorescent stains of day 12 control and LY294002-treated kidney organoids. Boxed regions are magnified. Inset in j shows absence of detectable HNF4A protein (orange) in day 12 samples. Scale bars: 10 microns. m Whole-mount immunofluorescent stain of day 12 control and LY294002-treated kidney organoids. Insets highlight JAG1 and HNF1B protein detection. Scale bars: 500 microns. n Quantification of JAG1 + and HNF1B + nephron size (µm 2 ) and HNF1B + intensity (RFU) for n = 3 day 12 organoids each, across all positive segments. SEM error bars shown. Statistical significance determined by two-sided Student’s t -test.

Journal: Nature Communications

Article Title: Controlling nephron precursor differentiation to generate proximal-biased kidney organoids with emerging maturity

doi: 10.1038/s41467-025-63107-9

Figure Lengend Snippet: a UMAP of single-cell RNA-sequencing from day 10 (pre-treatment), day 12 control, and day 12 PI3K inhibitor (LY294002)-treated kidney organoid nephrons. Cells are colored by sample with marker gene annotations. b Heatmap of Z-scores for hierarchically clustered differentially expressed genes across samples. Representative genes are listed, with a Z-score legend. c Feature plots of genes enriched in each sample group from the differentially expressed gene list. d Feature plots of selected genes for each group based on sample characteristics. For c , d human nephron single-cell detection (Supplementary Fig. ) is shown on the left, organoid plot on the right. e UMAP of single-cell RNA-sequencing from day 12 control and day 12 LY294002-treated kidney organoid nephrons. Cells match a but exclude day 10 sample. Cells are colored by sample with marker gene annotations. f Heatmap of log 2 fold change (log 2 FC) for differentially expressed genes, calculated as the ratio of LY294002-treated to control aggregate expression. Representative genes are listed with a log 2 FC legend. g Feature plots of genes enriched in each sample from the differentially expressed gene list. Human nephron single-cell (Supplementary Fig. ) detection is on the left, organoid plot on the right. h Split violin plots of genes from the differentially expressed gene list. Top two rows show genes enriched in day 12 control cells; bottom two rows show genes enriched in day 12 LY294002-treated cells. Plot colors match sample colors from ( e ). i Gene ontology terms for the top 50 differentially expressed genes per sample. Top graph: day 12 control nephron cells; bottom graph: LY294002-treated nephron cells. j–l Whole-mount immunofluorescent stains of day 12 control and LY294002-treated kidney organoids. Boxed regions are magnified. Inset in j shows absence of detectable HNF4A protein (orange) in day 12 samples. Scale bars: 10 microns. m Whole-mount immunofluorescent stain of day 12 control and LY294002-treated kidney organoids. Insets highlight JAG1 and HNF1B protein detection. Scale bars: 500 microns. n Quantification of JAG1 + and HNF1B + nephron size (µm 2 ) and HNF1B + intensity (RFU) for n = 3 day 12 organoids each, across all positive segments. SEM error bars shown. Statistical significance determined by two-sided Student’s t -test.

Article Snippet: Primary antibodies used in this study were: WT1 (abcam, ab89901, 1:1000), JAG1 (R&D Systems, AF599, 1:300), HNF1B (Thermo Fisher Scientific, MA5-24605, 1:500), HNF4A (R&D Systems, MAB4605, 1:200), CDH1 (BD Biosciences, 610181, 1:300), ZO-1 (Thermo Fisher Scientific, 33-9100, 1:200), PAX2 (R&D Systems, AF3364, 1:50), SIX1 (Cell Signaling Technology, 12891S, 1:300), HES1 (Cell Signaling Technology, 11988, 1:300), POU3F3 (Novus Biologicals, NBP1-49872, 1:500), HNF4G (Thermo Fisher Scientific, PA5-82189, 1:200), LRP2 (My Bio Source, MBS690201, 1:500), HAVCR1 (R&D Systems, AF1750, 1:200), γH2AX (Cell Signaling Technology, 2577), LAMB1 (Santa Cruz Biotechnology, sc-33709, 1:250), ATP1A1 (Abcam, ab7671, 1:200), SOX9 (Abcam, ab185230, 1:300), PODXL (R&D Systems, AF1658, 1:200), PAX8 (Abcam, ab189249, 1:100), LEF1 (Santa Cruz Biotechnology, sc-374412, 1:200), LTL (Vector Laboratories, B-1325-2, 1:300), SLC12A1 (Sigma Aldrich, HPA018107, 1:200), TFAP2A (Santa Cruz Biotechnology, sc-12726, 1:200), Alexa 647-conjugated LRP2 (R&D Systems, FAB9578R, 1:100), and Alexa 594-conjugated LRP2 (R&D Systems, FAB9578T, 1:100).

Techniques: RNA Sequencing, Control, Marker, Expressing, Staining